Real-world study of trastuzumab deruxtecan for HER2 breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your breast cancer is advanced (unresectable or metastatic) and has been tested locally as HER2-positive, HER2-low, or HER2-ultralow.
- Your cancer has gotten worse after recent treatment (radiologic progression).
- Your doctor has decided you can receive trastuzumab deruxtecan (T-DXd) and it is already scheduled for you.
- You can read and understand German or English, and you sign consent.
- You have not started T-DXd more than 30 days before the study enrollment paperwork is recorded.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This study is testing a new drug called trastuzumab deruxtecan (also known as T-DXd) in women with advanced breast cancer that is hormone receptor positive and has a very low level of HER2 (called HER2-ultralow). The trial aims to see if this drug can help shrink or slow the growth of the cancer in this specific group of patients.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This study looks at how well the drug Enhertu works for patients with HER2-low breast cancer that has spread. If you are already planning to start Enhertu, researchers will collect data from your regular care to learn more about its effectiveness.
This study tests the safety of the drug Trastuzumab Deruxtecan (T-DXd) in Indian patients with a specific type of advanced breast cancer (called HER2-positive) that has spread and cannot be removed by surgery. It is for patients who have already received anti-HER2 treatment.
This study looks at how well the drug Trastuzumab Deruxtecan works and how safe it is in real-world patients with advanced stomach or gastroesophageal cancer whose tumors are HER2-positive. The goal is to gather more information beyond what was learned in clinical trials.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.